FIGURE 5.

Inhibition of disease activity in NZB/NZW mice by BMS-986126. Mice were dosed orally with vehicle or 0.3, 1, 3, or 10 mg/kg/d BMS-986126, or with 1 mg/kg/d dexamethasone (DEX). Following 25 wk of dosing, several biomarkers of disease activity were assessed, including protein (A) and NGAL (B) concentrations in urine, plasma titers of dsDNA-specific autoantibodies (C), plasma levels of IL-12p40 (D), numbers of splenic IFN-α⁺ pDCs (E), expression of IFIT1 mRNA in blood (F), intensity of Ig deposition in the kidney (G), and kidney histology as visualized by H&E staining with ×20 magnification (H and I). Asterisks indicate glomerular changes characterized by mesangial thickening, cellular infiltration, and sclerosis/fibrosis. Preonset values are from NZB/NZW mice at 10 wk of age. Means and SEM for each group are plotted. Data are from one experiment with 14 animals per group. *p < 0.01, **p < 0.001, ***p < 0.0001 versus vehicle by one-way ANOVA with a Dunnett test.